Litigation Details for Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. (D. Del. 2022)
✉ Email this page to a colleague
Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. (D. Del. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-03-04 |
| Court | District Court, D. Delaware | Date Terminated | 2022-03-28 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 10,220,155; 10,335,462; 10,357,616; 10,376,652; 7,762,994; 8,114,833; 8,129,343; 8,536,122; 8,579,869; 8,684,969; 8,920,383; 9,108,002; 9,132,239; 9,457,154; 9,616,180; 9,687,611; 9,775,953; 9,861,757; RE46,363 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc.
Details for Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-03-03 | 1 | Complaint | the “’953 patent”), 9,861,757 (the “’757 patent”), 10,220,155 (the “’155 patent”), 10,335,462 (the “’… COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 10,220,155 128. Novo Nordisk re-alleges … United States Patent Nos. 7,762,994 (the “’994 patent”), 8,114,833 (the “’833 patent”), 8,129,343 (the…(the “’343 patent”), 8,536,122 (the “’122 patent”), 8,579,869 (the “’869 patent”), 8,684,969 (that “’…“’969 patent”), 8,920,383 (the “’383 patent”), 9,108,002 (the “’002 patent”), 9,132,239 (the “’239 patent | External link to document |
| 2022-03-29 | 8 | Patent/Trademark Report to Commissioner of Patents | ; 9,132,239 B2; 9,457,154 B2; 9,687,611 B2; 10,335,462 B2. (Attachments: # 1 Notice of Voluntary Dismissal… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2; …2022 28 March 2022 1:22-cv-00295 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
